drugset / Trial / NCT04414748

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A

NCT04414748

Phase 3 Completed 400 enrolled ShangHai Ji Ai Genetics & IVF Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized trial aims to compare the euploid rate of blastocysts between PPOS and GnRH antagonist protocols in patients undergoing PGT-A. Infertile women who have medical indication for PGT-A will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger. The primary outcome is the euploidy rate of blastocysts.

Timeline

Start
2020-06-10
Primary completion
2024-12-01
Completion
2025-05-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cetrorelix Other / unclassified 0.25 mg
Subject Dydrogesterone Other / unclassified 10 mg

Indications

No indication recorded.